Cell reports. Medicine

Testing an mRNA vaccine made from the first cow H5N1 virus found in humans

Updated

Abstract

An mRNA vaccine encoding hemagglutinin from A/Texas/37/2024 may confer complete protection against lethal H5N1 influenza in murine models.

  • Both wild-type and modified hemagglutinin vaccines elicit robust and durable immune responses.
  • The vaccine stimulates a balanced Th1/Th2 immune response.
  • Cross-clade binding antibody responses are observed, with improved effectiveness against specific clades at a 1 μg dose.
  • Pre-existing immunity to H1 does not reduce the immunogenicity of the H5 vaccine.
  • In avian species, the vaccine provides full protection against lethal strains of H5N1.
  • The vaccine shows a favorable safety profile in rat models.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Declaration of interests J. Lu, Y. Liu, T. Jiang, and H. Gu are employees of Shanghai RNACure Biopharma Company, which collaborated in the development of the vaccine. J. Lin, J. Lu, Y. Liu, and T. Jiang are inventors of patent CN119264001A, which is owned by Shanghai RNACure Biopharma Company. Q. Zhang, Y. Quan, H. Li, and S. Feng. are inventors on patent application CN202510125661.5, which covers the mRNA sequence design described in this manuscript. The remaining authors declare no competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free